Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

CLDX | Celldex Therapeutics Inc.

IndexRUT P/E- EPS (ttm)-2.40 Insider Own1.38% Shs Outstand47.20M Perf Week4.11%
Market Cap1.29B Forward P/E- EPS next Y-2.98 Insider Trans0.00% Shs Float46.61M Perf Month-3.39%
Income-113.13M PEG- EPS next Q-0.68 Inst Own107.28% Short Float / Ratio13.06% / 14.25 Perf Quarter-22.00%
Sales3.25M P/S397.57 EPS this Y-9.76% Inst Trans2.46% Short Interest6.09M Perf Half Y-21.39%
Book/sh5.87 P/B4.65 EPS next Y-13.31% ROA-32.22% Target Price59.57 Perf Year-1.19%
Cash/sh5.32 P/C5.14 EPS next 5Y- ROE-35.21% 52W Range24.89 - 48.40 Perf YTD-38.66%
Dividend- P/FCF- EPS past 5Y26.01% ROI-40.51% 52W High-43.51% Beta2.14
Dividend %- Quick Ratio16.93 Sales past 5Y-13.34% Gross Margin13.18% 52W Low9.84% ATR1.09
Employees148 Current Ratio16.93 Sales Q/Q64.42% Oper. Margin-3725.25% RSI (14)44.86 Volatility3.87% 3.77%
OptionableYes Debt/Eq0.01 EPS Q/Q16.17% Profit Margin-3475.70% Rel Volume1.36 Prev Close26.51
ShortableYes LT Debt/Eq0.01 EarningsAug 08 AMC Payout- Avg Volume427.23K Price27.34
Recom1.57 SMA20-0.31% SMA50-10.65% SMA200-25.43% Volume583,043 Change3.13%
Date Action Analyst Rating Change Price Target Change
Aug-22-23Initiated Wells Fargo Underweight $21
Sep-17-21Initiated Jefferies Buy $66
Sep-10-21Initiated SVB Leerink Outperform $68
Jul-22-21Initiated Guggenheim Buy $66
Feb-21-20Initiated Cantor Fitzgerald Overweight $8
Aug-01-17Resumed H.C. Wainwright Buy $10
Nov-07-16Initiated Aegis Capital Buy
Mar-08-16Downgrade Jefferies Buy → Hold
Mar-07-16Downgrade Wedbush Outperform → Neutral $4
Mar-07-16Downgrade Leerink Partners Outperform → Mkt Perform
Sep-26-23 07:01AM
Sep-25-23 08:31AM
Aug-22-23 09:35AM
Aug-08-23 05:30PM
04:01PM Loading…
Jul-11-23 08:01AM
Jul-06-23 08:01AM
Jun-10-23 10:45AM
Jun-08-23 04:01PM
Jun-02-23 08:01AM
May-31-23 08:01AM
May-23-23 06:10AM
May-15-23 08:01AM
May-04-23 06:05PM
05:03PM Loading…
Apr-18-23 05:58AM
Apr-12-23 08:13AM
Mar-29-23 09:01AM
Mar-02-23 05:40AM
Feb-28-23 04:01PM
Feb-27-23 10:25AM
Feb-26-23 09:00AM
Feb-16-23 04:01PM
Feb-15-23 07:00AM
Feb-03-23 07:01AM
Jan-18-23 02:38PM
Dec-06-22 06:00AM
Dec-02-22 09:31AM
09:45AM Loading…
Nov-27-22 09:45AM
Nov-10-22 04:01PM
Nov-09-22 05:25PM
Nov-02-22 10:01AM
Nov-01-22 10:01AM
Aug-08-22 05:25PM
Jul-21-22 08:00AM
Jul-08-22 09:26AM
Jul-06-22 09:55AM
Jul-05-22 03:57PM
Jul-04-22 11:49AM
Jul-01-22 04:11PM
Jun-30-22 06:01PM
Jun-22-22 09:24AM
Jun-21-22 08:00AM
Jun-20-22 10:35AM
Jun-16-22 04:01PM
Jun-06-22 04:05PM
May-19-22 09:23AM
May-11-22 08:13AM
May-06-22 08:10AM
May-05-22 05:55PM
May-04-22 08:25AM
Feb-28-22 04:01PM
Feb-22-22 04:01PM
Feb-17-22 03:07AM
Feb-13-22 07:47AM
Feb-10-22 04:05PM
Feb-02-22 01:38PM
Jan-10-22 08:40AM
Dec-15-21 04:57AM
Dec-11-21 06:53PM
Dec-08-21 08:01AM
Nov-12-21 07:00AM
Nov-11-21 07:01AM
Nov-09-21 06:15PM
Oct-28-21 03:05PM
Oct-25-21 11:51AM
Sep-29-21 08:13AM
Sep-24-21 07:01AM
Sep-23-21 08:01AM
Sep-16-21 07:01AM
Sep-14-21 10:31AM
Sep-13-21 09:01AM
Aug-25-21 03:55PM
Aug-05-21 06:05PM
Jul-29-21 03:05PM
Jul-24-21 07:04AM
Jul-18-21 03:39AM
Jul-16-21 04:01PM
Jul-14-21 03:21PM
Jul-13-21 08:30PM
Jul-12-21 04:27PM
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KELER TIBOREXECUTIVE VP & CSODec 07Option Exercise2.7816,86046,87124,217Dec 09 04:07 PM
KELER TIBOREXECUTIVE VP & CSODec 07Sale36.9316,860622,6117,357Dec 09 04:07 PM